Overview

Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone

Status:
Withdrawn

Trial end date:
2023-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to access the safety of combining sodium selenite with abiraterone and to see what doses of sodium selenite can be safely combined with abiraterone in treating castration resistant prostate cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Stanford University

Treatments:

Abiraterone Acetate
Prednisone
Selenious Acid
Sodium Selenite